Landec Corp \Ca\ LNDC
We take great care to ensure that the data presented and summarized in this overview for LANDEC CORP \CA\ is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LNDC
View all-
Wynnefield Capital Inc New York, NY4.7MShares$00.0% of portfolio
-
Legion Partners Asset Management, LLC Los Angeles, CA4.43MShares$00.0% of portfolio
-
Greenhaven Road Investment Management, L.P. Greenwich, CT3.69MShares$00.0% of portfolio
-
325 Capital LLC New York, NY2.16MShares$00.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.61MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY1.45MShares$00.0% of portfolio
-
Geode Capital Management, LLC Boston, MA775KShares$00.0% of portfolio
-
Morgan Stanley New York, NY740KShares$00.0% of portfolio
-
Grizzlyrock Capital, LLC Chicago, IL735KShares$04.06% of portfolio
-
State Street Corp Boston, MA531KShares$00.0% of portfolio
Latest Institutional Activity in LNDC
Top Purchases
Top Sells
About LNDC
Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, and filled products. In addition, it offers O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products. The company operates in the United States, Canada, and internationally. Landec Corporation was incorporated in 1986 and is headquartered in Santa Maria, California.
Insider Transactions at LNDC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2025
|
Nelson Obus Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+12.37%
|
-
|
|
Jul 15
2025
|
Christopher S Kiper Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+20.09%
|
-
|
|
Jul 15
2025
|
Paul Harold Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+30.69%
|
-
|
|
Jul 15
2025
|
Humberto Calheiros Antunes Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+29.3%
|
-
|
|
Jul 15
2025
|
Matthew E Korenberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+30.69%
|
-
|
|
Jul 15
2025
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+30.69%
|
-
|
|
Jul 15
2025
|
Lovas Katrina Houde Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+15.13%
|
-
|
|
Jul 15
2025
|
Joshua Schechter Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,506
+15.4%
|
-
|
|
Jul 08
2025
|
Thomas D. Salus Chief Legal & Administration |
SELL
Payment of exercise price or tax liability
|
Direct |
11,022
-4.37%
|
$88,176
$8.19 P/Share
|
|
Jul 08
2025
|
Thomas D. Salus Chief Legal & Administration |
BUY
Exercise of conversion of derivative security
|
Direct |
37,000
+12.8%
|
-
|
|
Jul 08
2025
|
Paul Josephs Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
54,857
-7.97%
|
$438,856
$8.19 P/Share
|
|
Jul 08
2025
|
Paul Josephs Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+17.9%
|
-
|
|
Jul 08
2025
|
Ryan David Lake Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,806
-8.36%
|
$262,448
$8.19 P/Share
|
|
Jul 08
2025
|
Ryan David Lake Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+16.05%
|
-
|
|
May 28
2025
|
Aron R. English |
SELL
Open market or private sale
|
Indirect |
150,419
-36.28%
|
$1,052,933
$7.12 P/Share
|
|
May 27
2025
|
Aron R. English |
SELL
Open market or private sale
|
Indirect |
1,139,504
-73.32%
|
$6,837,024
$6.5 P/Share
|
|
May 23
2025
|
Aron R. English |
SELL
Open market or private sale
|
Indirect |
96,137
-5.83%
|
$576,822
$6.75 P/Share
|
|
May 20
2025
|
Paul Josephs Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
21,532
-3.85%
|
$129,192
$6.63 P/Share
|
|
May 13
2025
|
Aron R. English |
SELL
Open market or private sale
|
Indirect |
12,334
-0.74%
|
$86,338
$7.0 P/Share
|
|
May 12
2025
|
Aron R. English |
SELL
Open market or private sale
|
Indirect |
45,698
-2.68%
|
$319,886
$7.03 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 429K shares |
|---|---|
| Exercise of conversion of derivative security | 337K shares |
| Open market or private purchase | 1.77M shares |
| Open market or private sale | 1.49M shares |
|---|---|
| Payment of exercise price or tax liability | 172K shares |